Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice

Malignant pleural mesothelioma (MPM) is the most common form of mesothelioma and the type most often studied in prospective clinical trials.This review reports the trials that have shaped first-line treatment for patients with advanced/unresectable MPM and the real-world integration of first-line im...

Descripción completa

Detalles Bibliográficos
Autores principales: Offin, Michael, Rusch, Valerie W, Rimner, Andreas, Adusumilli, Prasad S, Zauderer, Marjorie G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355824/
https://www.ncbi.nlm.nih.gov/pubmed/35708504
http://dx.doi.org/10.1093/oncolo/oyac113
_version_ 1784763382478405632
author Offin, Michael
Rusch, Valerie W
Rimner, Andreas
Adusumilli, Prasad S
Zauderer, Marjorie G
author_facet Offin, Michael
Rusch, Valerie W
Rimner, Andreas
Adusumilli, Prasad S
Zauderer, Marjorie G
author_sort Offin, Michael
collection PubMed
description Malignant pleural mesothelioma (MPM) is the most common form of mesothelioma and the type most often studied in prospective clinical trials.This review reports the trials that have shaped first-line treatment for patients with advanced/unresectable MPM and the real-world integration of first-line immune checkpoint inhibitors into clinical practice.
format Online
Article
Text
id pubmed-9355824
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-93558242022-08-09 Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice Offin, Michael Rusch, Valerie W Rimner, Andreas Adusumilli, Prasad S Zauderer, Marjorie G Oncologist Commentaries Malignant pleural mesothelioma (MPM) is the most common form of mesothelioma and the type most often studied in prospective clinical trials.This review reports the trials that have shaped first-line treatment for patients with advanced/unresectable MPM and the real-world integration of first-line immune checkpoint inhibitors into clinical practice. Oxford University Press 2022-06-16 /pmc/articles/PMC9355824/ /pubmed/35708504 http://dx.doi.org/10.1093/oncolo/oyac113 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
spellingShingle Commentaries
Offin, Michael
Rusch, Valerie W
Rimner, Andreas
Adusumilli, Prasad S
Zauderer, Marjorie G
Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice
title Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice
title_full Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice
title_fullStr Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice
title_full_unstemmed Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice
title_short Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice
title_sort evolving landscape of initial treatments for patients with malignant pleural mesotheliomas: clinical trials to clinical practice
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355824/
https://www.ncbi.nlm.nih.gov/pubmed/35708504
http://dx.doi.org/10.1093/oncolo/oyac113
work_keys_str_mv AT offinmichael evolvinglandscapeofinitialtreatmentsforpatientswithmalignantpleuralmesotheliomasclinicaltrialstoclinicalpractice
AT ruschvaleriew evolvinglandscapeofinitialtreatmentsforpatientswithmalignantpleuralmesotheliomasclinicaltrialstoclinicalpractice
AT rimnerandreas evolvinglandscapeofinitialtreatmentsforpatientswithmalignantpleuralmesotheliomasclinicaltrialstoclinicalpractice
AT adusumilliprasads evolvinglandscapeofinitialtreatmentsforpatientswithmalignantpleuralmesotheliomasclinicaltrialstoclinicalpractice
AT zauderermarjorieg evolvinglandscapeofinitialtreatmentsforpatientswithmalignantpleuralmesotheliomasclinicaltrialstoclinicalpractice

Ejemplares similares